Patents Examined by James D. Schultz
  • Detection of small nucleic acids
    Patent number: 7851150
    Abstract: The present invention relates to compositions and methods for the detection and characterization of interfering RNAs such as micro RNAs (miRNAs) and small interfering RNAs (siRNAs) and other short nucleic acid molecules. More particularly, the present invention relates to methods for the detection and quantitation of interfering RNA expression. The present invention further provides for the detection of variants and types of miRNAs and siRNAs.
    Type: Grant
    Filed: December 18, 2003
    Date of Patent: December 14, 2010
    Assignee: Third Wave Technologies, Inc.
    Inventors: James E. Dahlberg, Hatim T. Allawi, Victor Lyamichev, Bruce P. Neri, Marilyn C. Olson-Munoz, LuAnne Chehak, Sarah M. Olson
  • Nucleic acid catalysts with endonuclease activity
    Patent number: 6831171
    Abstract: The present invention relates to novel Nucleic acid catalysts, methods of synthesis, and uses thereof.
    Type: Grant
    Filed: February 8, 2001
    Date of Patent: December 14, 2004
    Assignees: Yale University, Sirna Therapeutics, Inc.
    Inventors: Ronald Breaker, Leonid Beigelman
  • TREX, a novel gene of TRAF-interacting EXT gene family and diagnostic and therapeutic uses thereof
    Patent number: 6812326
    Abstract: This invention provides an isolated nucleic acid molecule encoding a Tumor necrosis factor Receptor-Associated Factor protein-interacting hereditary multiple extoses (TREX) protein and vectors comprising the isolated nucleic acid encoding TREX. This invention also provides a purified TREX protein and antibodies thereto. This invention further provides oligonucleotides capable of specifically hybridizing with the isolated nucleic acid molecule encoding TREX. This invention further provides an antisense oligonucleotide against a genomic DNA molecule encoding TREX. This invention further provides methods of: (1) inhibiting TREX protein interaction, (2) inhibiting overexpression of TREX protein, and (3) inhibiting growth of a tumor. This invention further provides assays for: (1) screening for compounds that inhibit TREX binding, (2) detecting predispositions to cancer comprising TREX mutations, and (3) diagnosing cancer comprising TREX mutations.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: November 2, 2004
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Taka-Aki Sato
  • Therapy of respiratory influenza virus infection using free and liposome-encapsulated ribonucleotides
    Patent number: 6544958
    Abstract: The present invention relates to novel ribonucleotide oligonucleotides (RNOs) that are specifically designed to inhibit viral replication. The RNOs are capable of binding to both the negative and positive strands of influenza RNA segments, thereby inhibiting the virus' ability to produce various viral components, thus inhibiting viral propagation, and effectively killing the virus at the intracellular sites of infection in the respiratory tract. The RNOs provided may act independently, or in combination to optimize their antiviral activity. In addition, the RNOs provided may be formulated in liposomes, which facilitate their therapeutic delivery to intracellular sites of infection, and additionally increase antiviral efficacies.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: April 8, 2003
    Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence of Her Majesty's Canadian Government
    Inventors: Jonathan P. H. Wong, Leslie P. Nagata